Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Respiration, Artificial | 4 | 2021 | 22116 | 0.22 | Why? |
| Clostridium Infections | 2 | 2019 | 595 | 0.21 | Why? |
| Pneumonia | 1 | 2021 | 5652 | 0.21 | Why? |
| Hypogonadism | 1 | 2021 | 196 | 0.20 | Why? |
| Hepatitis C, Chronic | 2 | 2018 | 973 | 0.19 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.18 | Why? |
| Hypokalemia | 1 | 2020 | 195 | 0.18 | Why? |
| Fibronectins | 1 | 2018 | 92 | 0.17 | Why? |
| Zanamivir | 1 | 2017 | 63 | 0.17 | Why? |
| Leishmaniasis, Visceral | 1 | 2017 | 85 | 0.16 | Why? |
| Sustained Virologic Response | 1 | 2018 | 378 | 0.16 | Why? |
| Infusions, Intravenous | 1 | 2020 | 1224 | 0.15 | Why? |
| Microarray Analysis | 1 | 2017 | 262 | 0.15 | Why? |
| Carotid Artery Diseases | 1 | 2017 | 251 | 0.13 | Why? |
| Endocarditis | 1 | 2019 | 368 | 0.13 | Why? |
| Respiratory Function Tests | 1 | 2020 | 1755 | 0.12 | Why? |
| Organ Dysfunction Scores | 1 | 2019 | 1475 | 0.12 | Why? |
| Oseltamivir | 1 | 2017 | 583 | 0.12 | Why? |
| Length of Stay | 2 | 2021 | 11042 | 0.12 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.12 | Why? |
| Antiviral Agents | 3 | 2020 | 41703 | 0.12 | Why? |
| HIV Infections | 4 | 2018 | 11620 | 0.12 | Why? |
| Aftercare | 1 | 2021 | 1637 | 0.11 | Why? |
| Seroconversion | 1 | 2021 | 2515 | 0.11 | Why? |
| Retrospective Studies | 9 | 2021 | 105322 | 0.10 | Why? |
| Hospital Mortality | 5 | 2021 | 22087 | 0.10 | Why? |
| Atherosclerosis | 1 | 2018 | 768 | 0.10 | Why? |
| Decision Support Techniques | 1 | 2017 | 903 | 0.10 | Why? |
| Bacteremia | 2 | 2019 | 1372 | 0.10 | Why? |
| Survival Analysis | 2 | 2020 | 7592 | 0.10 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.10 | Why? |
| Frailty | 1 | 2021 | 1432 | 0.10 | Why? |
| Non-alcoholic Fatty Liver Disease | 1 | 2018 | 907 | 0.09 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.09 | Why? |
| Carcinoma, Hepatocellular | 1 | 2018 | 1222 | 0.09 | Why? |
| Anti-HIV Agents | 2 | 2017 | 2209 | 0.09 | Why? |
| Recurrence | 1 | 2017 | 3675 | 0.08 | Why? |
| Tissue and Organ Procurement | 1 | 2018 | 1277 | 0.08 | Why? |
| Spain | 3 | 2020 | 15545 | 0.08 | Why? |
| Carotid Intima-Media Thickness | 2 | 2018 | 179 | 0.08 | Why? |
| Drug Therapy, Combination | 1 | 2020 | 7268 | 0.08 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.07 | Why? |
| Interleukin-6 | 2 | 2020 | 7522 | 0.07 | Why? |
| Patient Discharge | 1 | 2021 | 5696 | 0.07 | Why? |
| Aged | 12 | 2021 | 215776 | 0.07 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.07 | Why? |
| Europe | 1 | 2021 | 12702 | 0.07 | Why? |
| Risk Factors | 7 | 2021 | 71621 | 0.07 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.07 | Why? |
| Middle Aged | 13 | 2021 | 270681 | 0.07 | Why? |
| Age Factors | 3 | 2021 | 21039 | 0.06 | Why? |
| Male | 16 | 2021 | 367725 | 0.06 | Why? |
| Time-to-Treatment | 1 | 2020 | 5883 | 0.06 | Why? |
| Time Factors | 3 | 2021 | 31397 | 0.06 | Why? |
| Humans | 22 | 2021 | 930598 | 0.06 | Why? |
| Sepsis | 1 | 2019 | 3517 | 0.06 | Why? |
| Incidence | 2 | 2021 | 25622 | 0.06 | Why? |
| Brain Chemistry | 1 | 2021 | 49 | 0.06 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.06 | Why? |
| Coinfection | 2 | 2018 | 6820 | 0.05 | Why? |
| Transplant Recipients | 1 | 2017 | 4982 | 0.05 | Why? |
| Female | 13 | 2021 | 380317 | 0.05 | Why? |
| Immunocompromised Host | 1 | 2017 | 5150 | 0.05 | Why? |
| Comorbidity | 3 | 2021 | 34796 | 0.05 | Why? |
| Prognosis | 2 | 2021 | 32490 | 0.05 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.05 | Why? |
| Adult | 10 | 2021 | 244371 | 0.05 | Why? |
| Kidney Transplantation | 1 | 2018 | 5397 | 0.04 | Why? |
| DNA, Ribosomal | 1 | 2017 | 112 | 0.04 | Why? |
| Antiprotozoal Agents | 1 | 2017 | 83 | 0.04 | Why? |
| Treatment Outcome | 2 | 2020 | 51732 | 0.04 | Why? |
| Colon | 1 | 2021 | 669 | 0.04 | Why? |
| Testosterone | 1 | 2021 | 596 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.03 | Why? |
| Lipopolysaccharide Receptors | 1 | 2017 | 357 | 0.03 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.03 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.03 | Why? |
| Fungi | 1 | 2017 | 471 | 0.03 | Why? |
| Magnetic Resonance Spectroscopy | 1 | 2018 | 881 | 0.03 | Why? |
| Administration, Intravenous | 1 | 2017 | 1115 | 0.03 | Why? |
| Insulin Resistance | 1 | 2018 | 669 | 0.03 | Why? |
| Biomarkers | 3 | 2021 | 23361 | 0.03 | Why? |
| Influenza, Human | 1 | 2017 | 10779 | 0.03 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.03 | Why? |
| Area Under Curve | 1 | 2019 | 2564 | 0.03 | Why? |
| Patient Readmission | 1 | 2021 | 1543 | 0.03 | Why? |
| Feasibility Studies | 1 | 2021 | 3467 | 0.03 | Why? |
| Staphylococcal Infections | 1 | 2019 | 1099 | 0.02 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.02 | Why? |
| Odds Ratio | 1 | 2021 | 5861 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2019 | 5440 | 0.02 | Why? |
| Prevalence | 2 | 2021 | 25773 | 0.02 | Why? |
| Liver | 1 | 2021 | 4007 | 0.02 | Why? |
| ROC Curve | 1 | 2019 | 6024 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2019 | 6543 | 0.02 | Why? |
| Survival Rate | 1 | 2021 | 9206 | 0.02 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.02 | Why? |
| Double-Blind Method | 1 | 2017 | 5988 | 0.02 | Why? |
| Saliva | 1 | 2021 | 4679 | 0.02 | Why? |
| Body Mass Index | 1 | 2017 | 4306 | 0.02 | Why? |
| Databases, Factual | 1 | 2019 | 6248 | 0.02 | Why? |
| Cause of Death | 1 | 2017 | 4823 | 0.02 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| Quality of Life | 1 | 2021 | 9820 | 0.01 | Why? |
| Immunosuppressive Agents | 1 | 2017 | 6331 | 0.01 | Why? |
| Pandemics | 3 | 2021 | 389249 | 0.01 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.01 | Why? |
| Heart Failure | 1 | 2019 | 6638 | 0.01 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.01 | Why? |
| Risk Assessment | 1 | 2018 | 25439 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |
| Adolescent | 1 | 2017 | 86841 | 0.00 | Why? |
| Young Adult | 1 | 2017 | 93724 | 0.00 | Why? |
Merino's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(115)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(98)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_